Acetylenyl-pyrazolo-pyrimidine derivatives

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I):

• wherein
• either E and J are N, G is C and one of L or M is N and the other is CH;
• or L and G are N, E is C, and J and M are CH;
• or J, G and L are N, E is C and M is CH;
• or E and L are N, J and M are CH and G is C;
• R1 is H, halo, CF3, CHF2, or C1-6-alkyl;
• R2 is H, halo, C1-6-alkyl, C1-6-alkoxy, CF3 or CHF2;
• R3 is H, —C(CH3)2OH, or linear C1-4-allyl or C3-4-cycloalkyl each of which is optionally substituted by one or more substituents selected from the group consisting of 1 to 6 F and 1 to 2 OH;
• A is selected from the group consisting of aryl or 5 or 6-membered heteroaryl each of which is optionally substituted by one to four Ra;
• Ra is halo, hydroxy, cyano, CF3, NReRf, C1-6-alkyl optionally substituted by amino or by hydroxy, C1-6-alkoxy, C3-4-cycloalkyl, CO—NRbRc, SO2—NRbRc, or SO2—Rd;
• Rb and Rc are the same or different and are selected from the group consisting of:
• H;
• straight or branched C1-6-alkyl optionally substituted by one or more substituents selected from the group consisting of:
• F, cyano, hydroxy, C1-6-alkoxy, —NH—C(O)—O—C1-6-alkyl, amino, (C1-6-alkyl)amino, di(C1-6-alkyl)amino, C3-6-cycloalkyl, heterocycloalkyl having 5 or 6 ring atoms, aryl and 5 or 6-membered heteroaryl;
• C3-6-cycloalkyl;
• aryl;
• and
• heteroaryl;
• or Rb and Rc, together with the nitrogen atom to which they are attached, form a heterocyclic ring of 4 to 6 ring members which are optionally substituted by hydroxy or by C1-6-alkyl;
• Rd is OH or C1-6-alkyl;
• and
• Re and Rf are each independently H, C1-6-alkyl optionally substituted by hydroxy, —C(O)—C1-6-alkyl, or S(O)2—C1-6-alkyl,
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.